Our results indicate that combined BMAL1, CLOCK, CRY1, PER1, PER2, and melatonin could be potential biomarkers for evaluating the sleep-wake rhythm disturbances of PD patients, which may help improve the accuracy of the clinical assessment and subjective sleep questionnaires. This evidence concerns the gene PER2 and Parkinson disease.